Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri: The Risk of Revival

This article was originally published in RPM Report

Executive Summary

Biogen Idec brilliantly convinced FDA's advisory experts to let the multiple sclerosis drug back on the market. FDA and the drug industry should prepare for the worst. One projection has 100,000 patients eligible for the immunosuppressant once it returns to the market. If there's significant penetration of that population, the drug's discoverer says it could be the setting for a public health disaster.

You may also be interested in...



The FDA Roundtable Part II: REMS, Outcomes Studies and Drug Withdrawals

In Part II of The RPM Report’s roundtable discussion with three top FDA officials, the importance and implementation of FDA’s new REMS authorities, drug withdrawal precedents and the agency’s view of outcomes studies are the focus of the discussion.

Safety Panic: Tysabri, Byetta and the Challenge of Risk Communication on Wall Street

There is no question someone is over-reacting to safety issues with Biogen Idec/Elan's Tysabri and Lilly/Amylin's Byetta. But is it FDA-or investors?

The FDA Roundtable Part II: REMS, Outcomes Studies and Drug Withdrawals

In Part II of The RPM Report’s roundtable discussion with three top FDA officials, the importance and implementation of FDA’s new REMS authorities, drug withdrawal precedents and the agency’s view of outcomes studies are the focus of the discussion.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel